Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights

Periklis G. Foukas, Sotirios Tsiodras, Panagiota Economopoulou, Aris Spathis, Maria Mademli, Konstantinos Leventakos, Amanda Psyrri, Petros Karakitsos, Ioannis G. Panayiotides

Research output: Contribution to journalArticle

Abstract

The development of immune system modulating agents, such as immune checkpoint inhibitors (ICIs), has revolutionized cancer treatment. Nivolumab, a human monoclonal antibody against PD-1, has emerged as an efficient treatment for various malignancies, including non-small cell lung cancer (NSCLC); however, it is associated with important immune related side-effects, attributed to organ-specific inflammation, such as immune-mediated pneumonitis, a relatively uncommon, albeit potentially fatal adverse event. We herein present the unique case of severe interstitial pneumonitis with concomitant detection of Human Herpes Virus 6 (HHV-6) in a nivolumab treated patient with NSCLC. Potential pathogenetic mechanisms are discussed.

Original languageEnglish (US)
Pages (from-to)101-103
Number of pages3
JournalIDCases
Volume11
DOIs
StatePublished - Jan 1 2018

Keywords

  • Human Herpesvirus 6
  • Immunotherapy
  • Lung cancer
  • Nivolumab

ASJC Scopus subject areas

  • Infectious Diseases

Fingerprint Dive into the research topics of 'Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights'. Together they form a unique fingerprint.

  • Cite this

    Foukas, P. G., Tsiodras, S., Economopoulou, P., Spathis, A., Mademli, M., Leventakos, K., Psyrri, A., Karakitsos, P., & Panayiotides, I. G. (2018). Concomitant Human Herpes Virus 6 and nivolumab-related pneumonitis: Potential pathogenetic insights. IDCases, 11, 101-103. https://doi.org/10.1016/j.idcr.2018.01.013